NEW YORK, N.Y. and LONDON, U.K. — Eularis is announcing the release of an update to its report, “Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics and Metrics to Improve the Bottom Line.” Originally offered in February 2007, the comprehensive report has been revised to provide pharmaceutical marketers with a competitive edge and the latest research information.
“The pharmaceutical environment is turbulent, and what used to work to create an industry-wide growth of 20 percent, no longer does,” said the author of the report, Dr. Andree K. Bates, president of Eularis. “As market growth slows, the bottom line return for brands is under increased scrutiny, and every marketing dollar must count.”
Eularis identified a common problem faced by pharmaceutical companies – how to know which activities impact market share and by how much. The company assembled a group of world-leading mathematicians in the predictive analytics field, as well as thought leaders, to find the solution.
This report, in turn, analyzes how top pharmaceutical marketing leaders are handling pressing marketing return issues, and offers new ideas to apply. The detailed research addresses issues such as: ROI basics; practical skills marketers need for measuring marketing effectiveness; tools and best practices that make a difference; measurement principles that drive successful marketing measurement; how to propel strategy, growth, and bottom line return; plus an array of case studies.
The report also explains what real people did to measure, improve, and prove bottom line return. It uncovers practices to predict how and where pharmaceutical marketing and sales investments will yield the highest market share and market share price. Readers will benefit from the step-by-step guidelines on successfully implementing approaches for real and measurable results available only in this report.
Dr. Andree Bates, president of Eularis, has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis and is the author of this must-have report for all pharmaceutical industry marketers.
To purchase this report, visit:
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches which are lengthy and whose reliance on historical or analogue data reduces their accuracy, Eularis’ proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions.
Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.
[tags]pharmal marketers, Eularis pharmaceutical analytics, Dr Andree K Bates[/tags]
For more information about Eularis, visit http://www.eularis.com.
All trademarks acknowledged.